- Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry161, 975–984 (2004).
- Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res.39(4), 421–429 (2006).
- Leweke FM, Koethe D, Pahlisch F et al. Antipsychotic effects of cannabidiol. Eur. Psychiatry24(Suppl. 1), 207 (2009).
- Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.134(4), 845–852 (2001).
- Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem. Res.30, 1037–1043 (2005).
- Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr.30, 271–280 (2008).
- Koethe D, Giuffrida A, Schreiber D et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry194(4), 371–372 (2009).
- Koob GF, Swerdlow NR. The functional output of the mesolimbic dopamine system. Ann NY Acad Sci.537, 216–227 (1988).
- Kalivas PW, Churchill L, Romanides A. Involvement of the pallidal-thalamocortical circuit in adaptive behavior. Ann. NY Acad. Sci.877, 64–70 (1999).
- Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry161, 975–984 (2004).
- Leweke FM, Koethe D, Pahlisch F et al. Antipsychotic effects of cannabidiol. Eur. Psychiatry24(Suppl. 1), 207 (2009).
- Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.134(4), 845–852 (2001).
- Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem. Res.30, 1037–1043 (2005).
- Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr.30, 271–280 (2008).
- Koethe D, Giuffrida A, Schreiber D et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry194(4), 371–372 (2009).